InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1 |
MKPLKVHSHYCHOC-AHTXBMBWSA-N |
CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F |
|
prostaglandin receptor agonist
An agonist that binds to and activates prostaglandin receptors.
|
|
ophthalmology drug
Any compound used for the treatment of eye conditions or eye diseases.
antiglaucoma drug
Any drug which can be used to prevent or alleviate glaucoma, a disease in which the optic nerve is damaged, resulting in progressive, irreversible loss of vision. It is often, though not always, associated with increased pressure of the fluid in the eye.
antihypertensive agent
Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
prodrug
A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
|
|
View more via ChEBI Ontology
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoate
|
travoprost
|
WHO MedNet
|
travoprost
|
WHO MedNet
|
travoprost
|
ChemIDplus
|
travoprostum
|
WHO MedNet
|
isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
|
ChEBI
|
Travoprost
|
ChEMBL
|
Travatan
|
KEGG DRUG
|
Travatan Z
|
ChEBI
|
157283-68-6
|
CAS Registry Number
|
ChemIDplus
|
157283-68-6
|
CAS Registry Number
|
KEGG DRUG
|
8739060
|
Reaxys Registry Number
|
Reaxys
|
22050687
|
PubMed citation
|
Europe PMC
|
22167541
|
PubMed citation
|
Europe PMC
|
22259229
|
PubMed citation
|
Europe PMC
|
|